PCRX Q4 2024 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$187M+3.3% YoY

Gross Profit

$147M78.7% margin

Operating Income

$25M13.2% margin

Net Income

$16M8.6% margin

EPS (Diluted)

$0.34

QoQ Revenue Growth

+11.1%

Cash Flow

Operating Cash Flow

$33M

Free Cash Flow

$31M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$775M

Stockholders' Equity

$778M

Cash & Equivalents

$277M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$187M	$181M	+3.3%
Gross Profit	$147M	$134M	+10.3%
Operating Income	$25M	$33M	-25.5%
Net Income	$16M	$25M	-35.5%

Revenue Segments

Product

$187M51%

EXPAREL

$148M40%

ZILRETTA

$33M9%